Nicox (NICXF) General and Admin. Expense: $0.00 Mil (TTM As of Dec. 2025)


NICXF Nicox SA NICXF
37 GF Score
Price $0.30
GF Value $0.56
! 2 Warning Signs
View Full Analysis

What is Nicox General and Admin. Expense?

Nicox NICXF 37 General and Admin. Expense is $0.00 Mil as of Dec. 2025. GuruFocus rates NICXF with a GF Score™ of 37/100 and a GF Value™ of $0.56. The stock has 2 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Nicox's General and Admin. Expense for the six months ended in Dec. 2025 was $0.00 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Nicox General and Admin. Expense Related Terms

Nicox General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Nicox's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nicox General and Admin. Expense Chart

Nicox Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.16 7.16 3.20 4.43 0.00

Nicox Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NICXF
37GF Score
Nicox SA NICXF
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nicox General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of $0.00 Mil mean?
Nicox (NICXF) has a General and Admin. Expense of $0.00 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Nicox and its competitors.
Is Nicox's General and Admin. Expense too high?
Nicox's current General and Admin. Expense is $0.00 Mil. Overall, Nicox has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Nicox's General and Admin. Expense compare to VRTX and REGN?
Nicox's General and Admin. Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Nicox and its competitors. Nicox's current General and Admin. Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nicox stock overvalued right now?
Nicox (NICXF) has a current General and Admin. Expense of $0.00 Mil. The stock's GF Value™ is $0.56, compared to a current price of $0.30 — trading 46.4% below its estimated fair value. The current General and Admin. Expense is $0.00 Mil. Nicox's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Nicox (NICXF), the current General and Admin. Expense is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nicox (NICXF) Overvalued in 2026?

Based on GuruFocus' analysis, Nicox stock appears to be undervalued. The current stock price of $0.30 is trading 46.4% below its estimated GF Value™ of $0.56.

Key valuation signals for NICXF:

  • General and Admin. Expense: $0.00 Mil
  • GF Value™: $0.56 vs. price of $0.30 (46.4% below fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the NICXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nicox Business Description

Address Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
37GF Score

Get the complete analysis for NICXF

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price
$0.56
GF Value